Menu
Search
|

Menu

Close
X

Concert Pharmaceuticals Inc CNCE.OQ (NASDAQ Stock Exchange Global Market)

15.04 USD
-0.47 (-3.03%)
As of 4:36 PM GMT
chart
Previous Close 15.51
Open 15.55
Volume 36,521
3m Avg Volume 56,919
Today’s High 16.30
Today’s Low 15.03
52 Week High 23.07
52 Week Low 10.81
Shares Outstanding (mil) 22.69
Market Capitalization (mil) 347.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
11
FY17
144
FY16
0
EPS (USD)
FY18
-2.394
FY17
3.999
FY16
-2.281
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
4,235.86
8.39
Price to Book (MRQ)
vs sector
5.38
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
45.34
16.02
LT Debt to Equity (MRQ)
vs sector
45.34
11.35
Return on Investment (TTM)
vs sector
-45.62
13.82
Return on Equity (TTM)
vs sector
-58.35
15.24

EXECUTIVE LEADERSHIP

Richard Aldrich
Independent Chairman of the Board, Co-Founder, Since 2017
Salary: --
Bonus: --
Roger Tung
President, Chief Executive Officer, Co-Founder, Director, Since 2006
Salary: $517,402.00
Bonus: --
Marc Becker
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Nancy Stuart
Chief Operating Officer, Since 2007
Salary: $398,247.00
Bonus: --
Lynette Herscha
General Counsel, Secretary, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

65 Hayden Ave Ste 3000N
LEXINGTON   MA   02421-7994

Phone: +1781.8600045

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

SPONSORED STORIES